News
“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...
An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...
The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.
Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.
Pluvicto meanwhile brought in $980 million in 2023, and Novartis is modelling peak sales above $2 billion if it expands into earlier lines of therapy in PSMA-positive metastatic castration ...
Pluvicto has already overtaken predecessor radioligand therapy Lutathera (177Lu- oxodotreotide) for neuroendocrine tumours, which rose 22% to $149 million in the first quarter.
Novartis’ Pluvicto was the first targeted radioligand therapy for PSMA-positive metastatic prostate cancer to receive regulatory in March 2022.
Pluvicto seems to have fewer side effects than chemotherapy and is widely considered to be a “transformative drug,” for cancer care, Munzur said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results